Baricitinib Treatment in RNU7 ‐1‐Associated Aicardi–Goutières Syndrome in a South African Child: A Case Report
American Journal of Medical Genetics Part A · 2025
DOI: 10.1002/ajmg.a.63978 ↗Kurz gefasst
Fallbericht in der Zeitschrift American Journal of Medical Genetics Part A, 2025. Verfasst von Timothy F Spracklen und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Paediatrics and Child Health, University of Cape Town, Cape Town, South Africa. Hauptthemen laut MEDLINE: Autoimmune Diseases of the Nervous System, Azetidines, Nervous System Malformations, Pyrazoles. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Global Challenges Research Fund, Medical Research Council, Francis Crick Institute.
Abstract (Originalsprache)
Aicardi–Goutières syndrome (AGS) is a rare monogenic type I interferonopathy. Janus kinase (JAK) inhibition has emerged as a potential treatment for AGS. RNU7‐1 is one of the most recently discovered genes for AGS, and the clinical effects of JAK inhibition in these patients have not been reported. Here, we describe the diagnosis and treatment of a South African infant with RNU7‐1 ‐related AGS. The patient presented with developmental delay at age 5 months and was diagnosed with cerebral palsy due to a suspected congenital infection. By 18 months of age, he had a vasculitic rash, prominent generalized dystonia, persistent transaminitis, recurrent stomatitis, moderate‐range global developmental delay, and difficulty sleeping. AGS was considered after finding neuroimaging features of the disease; the diagnosis was confirmed when genetic investigations revealed two likely pathogenic RNU7‐1 compound heterozygous variants in the patient. Elevated interferon gene expression was noted in the patient and his mother who was a carrier of one RNU7‐1 variant. Baricitinib treatment was started, leading to modest, transient improvements in some clinical manifestations and a reduction in interferon‐stimulated gene expression. Liver function, dystonia, and neurological function did not improve even after increasing the baricitinib dose. Baricitinib was discontinued due to persistent and worsening adverse effects.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Paediatrics and Child Health, University of Cape Town, Cape Town, South Africa.
- Cape Heart Institute, University of Cape Town, Cape Town, South Africa.
- Cape Paediatric Rheumatology, Cape Town, South Africa.
- Mediclinic Constantiaberg, Cape Town, South Africa.
- MRC Human Genetics Unit, Institute of Genetics and Cancer, the University of Edinburgh, Edinburgh, UK.
- Laboratory of Neurogenetics and Neuroinflammation, University of Paris, Imagine Institute, Paris, France.
ORCID-Profile: Timothy F Spracklen, Yanick J Crow
Förderung
- Global Challenges Research Fund
- Medical Research Council
- Francis Crick Institute
- Cancer Research UK
- Agence Nationale de la Recherche
- Wellcome Trust
- European Research Council
- Crick African Network
Zitieren
APA
Spracklen, T. F., Akhalwaya, S., Ackermann, S., Uggenti, C., Seabra, L., Crow, Y. J., & Webb, K. (2025). Baricitinib Treatment in RNU7 ‐1‐Associated Aicardi–Goutières Syndrome in a South African Child: A Case Report. American Journal of Medical Genetics Part A. https://doi.org/10.1002/ajmg.a.63978
Vancouver
Spracklen TF, Akhalwaya S, Ackermann S, Uggenti C, Seabra L, Crow YJ, et al. Baricitinib Treatment in RNU7 ‐1‐Associated Aicardi–Goutières Syndrome in a South African Child: A Case Report. American Journal of Medical Genetics Part A. 2025. doi:10.1002/ajmg.a.63978
BibTeX
@article{Spracklen2025,
author = {Spracklen, Timothy F and Akhalwaya, Shehnaaz and Ackermann, Sally and Uggenti, Carolina and Seabra, Luis and Crow, Yanick J and Webb, Kate},
title = {Baricitinib Treatment in RNU7 ‐1‐Associated Aicardi–Goutières Syndrome in a South African Child: A Case Report},
journal = {American Journal of Medical Genetics Part A},
year = {2025},
doi = {10.1002/ajmg.a.63978}
}
EUVIMED